The Guidelines specifies three categories of post-approval changes of chemical drugs and corresponding required documents. The three categories are: 

(1) Changes for which supplemental application are required; 

(2) Changes required to be notified to medical products administrations; 

(3) Changes required to be specified in annual reports.